Full Press Release Details
TORONTOand GLIL YAM,Israel,Sept. 5, 2025/PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations inIsraelandGermany, today announced that it received notice from Nasdaq onSeptember 4, 2025that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least$2,500,000. The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market.
About IM Cannabis Corp.
IMC (Nasdaq:IMCC) is an international cannabis company that provides premium cannabis products to medical patients inIsraelandGermany, two of the largest medical cannabis markets. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates inIsraelthrough its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs inIsraelthat enable the safe delivery and quality control of IMC products throughout the entire value chain. InGermany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian andUnited Statessecurities laws (collectively, "forward-looking statements"). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus (collectively, the "Group") to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group's obligations;the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group's cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest inEastern Europeand theMiddle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry inIsrael; risks associated with the Company focusing on theIsraelandGermanymarkets; the Company's inability to realize upon the stated efficiencies and synergies of the Company as a global organization with domestic expertise inIsraelandGermany; the Company's inability to realize upon its retail presence, distribution capabilities and data-driven insights;the Company's ability to continue to comply with Nasdaq's continued listing requirements and its ability to execute its business strategy; and therisks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual report on Form 20-F datedMarch 31, 2025, which is available on the Company's issuer profile on SEDAR+ atwww.sedarplus.caand Edgar atwww.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:Oren Shuster, CEOIM Cannabis Corp.+972-77-3603504[email protected]
SOURCE IM Cannabis Corp.